The US researchers at the Baylor College of Medicine, Texas Children’s Hospital have said the follow-up observations mark the ...

Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and ...

Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, announced today that it has received a Notice of Allowance ...

GloboCare has received a Notice of Allowance from the China National Intellectual Property Administration for its patent ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

A patient has achieved over 18 years of remission from neuroblastoma, a type of nerve cell cancer, following treatment with ...

An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent ...

Some New York doctors are working on new ways to treat advanced cancers. Chimeric Antigen Receptor, or CAR, T-cell therapy ...

Scientists engineered T cells to protect instead of kill, potentially enabling targeted treatments for autoimmune disease and ...

Prostate-specific antigen responses were similar between transdermal estradiol and hormone therapy combined with androgen ...